LY2484595

DRUG4 trials

Sponsors

Eli Lilly and Company

Conditions

DyslipidemiaDyslipidemiasHealthy ParticipantsHealthy Volunteers

Phase 1

A Study of LY2484595 on Pharmacokinetics in Healthy Participants

CompletedNCT01448824

Eli Lilly and CompanyHealthy Participants

Start: 2011-10-31End: 2012-02-29Updated: 2019-04-02

A Study of LY2484595 on the Electrical Activity of the Heart

CompletedNCT01537887

Eli Lilly and CompanyHealthy Volunteers

Start: 2012-02-29End: 2012-06-30Updated: 2019-03-07

Phase 2

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

CompletedNCT01105975

Eli Lilly and CompanyDyslipidemia

Start: 2010-04-30End: 2011-06-30Updated: 2018-03-22

A Study of LY2484595 in Japanese Subjects

CompletedNCT01375075

Eli Lilly and CompanyDyslipidemias

Start: 2011-06-30End: 2012-03-31Updated: 2018-10-25

Related Papers

Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients.

2015-12-1844 citations

Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib

Journal of the American College of Cardiology2015-11-01114 citations

Abstract 12252: Effects of the Cholesteryl Ester Transfer Protein Inhibitor, Evacetrapib, Administered as Monotherapy or in Combination With Statins on Cholesterol Efflux and HDL Particles in Patients With Dyslipidemia

Circulation2014-11-258 citations

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

2011-11-01291 citations